Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Interview with CEO

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Mar 15, 2023 4:53pm

180 Views

Post# 35341041

Interview with CEO

A survey in the US found that 5% of people (approximately 12.2 million adults) reported experiencing chronic cough in the previous 12 months. The chronic cough market is expected to reach $11.38B by 2029.

I’ve been following AGN.c AGNPF (a clinical stage drug development company).

This interview with their CEO gives updates on the previously announced 180 patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough that will begin in Q3.

As well, they announced earlier this month they’re planning to be the first company globally to investigate DMT for TBI in humans and are working towards a Phase 2 clinical trial in Q4.

https://www.youtube.com/watch?v=zpvV0-fELgc

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario